ESMO26: Sac-TMT sets survival benchmark in recurrent endometrial cancer - Pharmaceutical Technology

Data for MSD and Kelun-Biotech's sac-TMT in endometrial cancer was presented at ESMO 2026. Data for MSD and Kelun-Biotech's sac-TMT in endometrial cancer was presented at ESMO 2026. Endometrial cancer is the sixth most common cancer in women worldwide. Credit: crystal light / Shutterstock.com Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. With a free Pharmaceutical Technology profile, you can: The leading site for news and procurement in the pharmaceutical industry var wpUserData = {"id":0,"email":false,"firstName":false,"lastName":false,"displayName":false,"phone":false,"company":false,"jobTitle":false,"industry":false,"country":false}; jQuery(document).ready(function() { jQuery('a[href*="/buy-reports"]').each(function() { var href = jQuery(this).attr('href');…

Source: Pharmaceutical Technology